

**SENATE BILL NO. 2134**

Introduced by

Senator J. Lee

(At the request of the State Board of Pharmacy)

1 A BILL for an Act to create and enact chapter 19-03.5 of the North Dakota Century Code,  
2 relating to a prescription drug monitoring program for controlled substances; to repeal section  
3 50-06-27 of the North Dakota Century Code, relating to a prescription drug monitoring program;  
4 to provide a penalty; and to declare an emergency.

5 **BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:**

6 **SECTION 1.** Chapter 19-03.5 of the North Dakota Century Code is created and  
7 enacted as follows:

8 **19-03.5-01. Definitions.**

- 9 1. "Board" means the state board of pharmacy.
- 10 2. "Central repository" means a place where electronic data related to the prescribing  
11 and dispensing of controlled substances is collected.
- 12 3. "Controlled substance" means a drug, substance, or immediate precursor defined  
13 in section 19-03.1-01, a tramadol-containing substance, and carisopordol.
- 14 4. "De-identified information" means health information that is not individually  
15 identifiable information because an expert has made that determination under  
16 title 45, Code of Federal Regulations, section 164.514 or direct identifiers and  
17 specified demographic information have been removed in accordance with the  
18 requirements of that section.
- 19 5. "Dispense" means to deliver a controlled substance to an ultimate user by or  
20 pursuant to the lawful order of a practitioner, including the prescribing,  
21 administering, packaging, labeling, or compounding necessary to prepare the  
22 substance for delivery.
- 23 6. "Dispenser" means an individual who delivers a controlled substance to the  
24 ultimate user but does not include a licensed hospital pharmacy that provides a

1           controlled substance for the purpose of inpatient hospital care or a licensed health  
2           care practitioner or other authorized individual in those instances when the  
3           practitioner administers a controlled substance to a patient.

4           7. "Individually identifiable health information" has the meaning set forth in title 45,  
5           Code of Federal Regulations, section 160.103.

6           8. "Patient" means an individual or the owner of an animal who is the ultimate user of  
7           a controlled substance for whom a prescription is issued or for whom a controlled  
8           substance is dispensed.

9           9. "Prescriber" means an individual licensed, registered, or otherwise authorized by  
10           the jurisdiction in which the individual is practicing to prescribe drugs in the course  
11           of professional practice.

12          10. "Program" means the prescription drug monitoring program implemented under  
13           this chapter.

14          **19-03.5-02. Requirements for prescription drug monitoring program.**

15          1. The board shall establish and maintain a program for the monitoring of prescribing  
16           and dispensing of all controlled substances.

17          2. Each dispenser shall submit to the board by electronic means information  
18           regarding each prescription dispensed for a controlled substance. The information  
19           submitted for each prescription must include all of the data elements in the  
20           American society for automation in pharmacy rules-based standard implementation  
21           guide for prescription monitoring programs issued August 31, 2005, version 003,  
22           release 000.

23          3. Each dispenser shall submit the information in accordance with transmission  
24           methods and frequency established by the board.

25          4. The board may issue an extension of time to a dispenser that is unable to submit  
26           prescription information by electronic means.

27          **19-03.5-03. Access to prescription information.**

28          1. Information submitted to the central repository is confidential and may not be  
29           disclosed except as provided in this section.

- 1           2. The board shall maintain procedures to ensure that the privacy, confidentiality, and  
2           security of patient information collected, recorded, transmitted, and maintained is  
3           not disclosed except as provided in this section.
- 4           3. Unless disclosure is prohibited by law, the board may provide data in the central  
5           repository to:
- 6           a. A prescriber for the purpose of providing medical care to a patient, a  
7           dispenser for the purpose of filling a prescription or providing pharmaceutical  
8           care for a patient, a prescriber or dispenser inquiring about the prescriber's or  
9           dispenser's own prescribing activity, or a prescriber or dispenser in order to  
10           further the purposes of the program;
- 11           b. An individual who requests the prescription information of the individual or the  
12           individual's minor child;
- 13           c. State boards and regulatory agencies that are responsible for the licensing of  
14           individuals authorized to prescribe or dispense controlled substances if the  
15           board or regulatory agency is seeking information from the central repository  
16           that is relevant to an investigation of an individual who holds a license issued  
17           by that board or regulatory agency;
- 18           d. Local, state, and federal law enforcement or prosecutorial officials engaged in  
19           the enforcement of laws relating to controlled substances who seek  
20           information for the purpose of an investigation or prosecution of the  
21           drug-related activity or probation compliance of an individual;
- 22           e. The department for purposes regarding the utilization of controlled substances  
23           by a medicaid recipient;
- 24           f. Workforce safety and insurance for purposes regarding the utilization of  
25           controlled substances by a claimant;
- 26           g. Judicial authorities under grand jury subpoena or court order or equivalent  
27           judicial process for investigation of criminal violations of controlled substances  
28           laws;
- 29           h. Public or private entities for statistical, research, or educational purposes after  
30           the information is de-identified with respect to any prescriber, dispenser, or  
31           patient who received a prescription for a controlled substance; or

1           i. A peer review committee which means any committee of a health care  
2           organization, composed of health care providers, employees, administrators,  
3           consultants, agents, or members of the health care organization's governing  
4           body, which conducts professional peer review as defined in chapter 23-34.

5           4. The board shall maintain a record of each person who requests information from  
6           the central repository. The board may use the records to document and report  
7           statistics and outcomes. The board may provide records of the requests for  
8           information to:

9           a. A board or regulatory agency responsible for the licensing of individuals  
10           authorized to prescribe or dispense controlled substances that is engaged in  
11           an investigation of the individual who submitted the request for information  
12           from the central repository; and

13           b. Local, state, and federal law enforcement or prosecutorial officials engaged in  
14           the enforcement of laws relating to controlled substances for the purpose of  
15           an active investigation of an individual who requested information from the  
16           central repository.

17           **19-03.5-04. Authority to contract.** The board is authorized to contract with another  
18           agency of this state or with a private vendor to facilitate the effective operation of the  
19           prescription drug monitoring program. Any contractor is bound to comply with the provisions  
20           regarding confidentiality of prescription drug information in this chapter and is subject to  
21           termination or sanction or both for unlawful acts.

22           **19-03.5-05. Immunity.** Nothing in this chapter requires a prescriber or dispenser to  
23           obtain information about a patient from the central repository prior to prescribing or dispensing a  
24           controlled substance. A prescriber, dispenser, or other health care practitioner may not be held  
25           liable in damages to any person in any civil action on the basis that the prescriber, dispenser, or  
26           other health care practitioner did or did not seek to obtain information from the central  
27           repository. Unless there is shown a lack of good faith, the board, any other state agency, a  
28           prescriber, dispenser, or any other individual in proper possession of information provided  
29           under this chapter may not be subject to any civil liability by reason of:

30           1. The furnishing of information under the conditions provided in this chapter;

31           2. The receipt and use of, or reliance on, such information;

- 1           3.   The fact that any such information was not furnished; or  
2           4.   The fact that such information was factually incorrect or was released by the board  
3                 to the wrong person or entity.

4           **19-03.5-06. Extraterritorial application.** Nothing in this chapter may be construed to  
5 prohibit the disclosure of information about a patient from the prescription drug monitoring  
6 program to a practitioner or controlled substances monitoring system in another state to the  
7 extent otherwise authorized by law, if the disclosure to a practitioner or the prescription drug  
8 monitoring program located in this state is authorized by this chapter.

9           **19-03.5-07. Authority to adopt rules.** The board may adopt rules that set forth the  
10 procedures and methods for implementing this chapter.

11           **19-03.5-08. Reporting unlawful acts and penalties.**

12           1.   The board may report to a dispenser's licensing board any dispenser who  
13                 knowingly fails to submit prescription drug monitoring information to the board as  
14                 required by this chapter or who knowingly submits incorrect prescription  
15                 information to the board.

16           2.   A person, including a vendor, who uses or discloses prescription drug monitoring  
17                 information in violation of this chapter is subject to the penalty provided in section  
18                 12.1-13-01.

19           **SECTION 2. REPEAL.** Section 50-06-27 of the North Dakota Century Code is  
20 repealed.

21           **SECTION 3. EMERGENCY.** This Act is declared to be an emergency measure.